MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma

被引：6
|
作者：
Miller, Julie J. [1 ,2 ]
Cahill, Daniel P. [1 ,3 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Translat Neurooncol Lab, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Div Neurooncol, Dept Neurol, Boston, MA 02115 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA
来源：
NEURO-ONCOLOGY | 2020年 / 22卷 / 11期
关键词：
glioma; IDH1; mutation; temozolomide; TEMOZOLOMIDE; PROCARBAZINE; VINCRISTINE; PROGRESSION; LOMUSTINE; EVOLUTION; THERAPY; BENEFIT;
D O I：
10.1093/neuonc/noaa212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1553 / 1554
页数：2
相关论文
共 50 条
  • [21] MGMT promoter methylation in pediatric high-grade gliomas
    Matteo Fassan
    Evelyne Tassone
    Maurizio Onisto
    Giorgio Perilongo
    Domenico D’Avella
    Marina Paola Gardiman
    Child's Nervous System, 2011, 27 : 7 - 8
  • [22] MGMT promoter methylation in pediatric high-grade gliomas
    Fassan, Matteo
    Tassone, Evelyne
    Onisto, Maurizio
    Perilongo, Giorgio
    D'Avella, Domenico
    Gardiman, Marina Paola
    CHILDS NERVOUS SYSTEM, 2011, 27 (01) : 7 - 8
  • [23] MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
    Olivier J. Switzeny
    Markus Christmann
    Mirjam Renovanz
    Alf Giese
    Clemens Sommer
    Bernd Kaina
    Clinical Epigenetics, 2016, 8
  • [24] MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
    Switzeny, Olivier J.
    Christmann, Markus
    Renovanz, Mirjam
    Giese, Alf
    Sommer, Clemens
    Kaina, Bernd
    CLINICAL EPIGENETICS, 2016, 8
  • [25] The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature
    Victor M. Lu
    Kyle P. O’Connor
    Ashish H. Shah
    Daniel G. Eichberg
    Evan M. Luther
    Ricardo J. Komotar
    Michael E. Ivan
    Journal of Neuro-Oncology, 2020, 148 : 221 - 229
  • [26] The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature
    Lu, Victor M.
    O'Connor, Kyle P.
    Shah, Ashish H.
    Eichberg, Daniel G.
    Luther, Evan M.
    Komotar, Ricardo J.
    Ivan, Michael E.
    JOURNAL OF NEURO-ONCOLOGY, 2020, 148 (02) : 221 - 229
  • [27] Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status
    Cheng, Wen
    Ren, Xiufang
    Zhang, Chuanbao
    Han, Sheng
    Wu, Anhua
    JOURNAL OF NEURO-ONCOLOGY, 2017, 132 (02) : 207 - 218
  • [28] Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma
    Deng, Xiangyang
    Lin, Dongdong
    Chen, Bo
    Zhang, Xiaojia
    Xu, Xingxing
    Yang, Zelin
    Shen, Xuchao
    Yang, Liang
    Lu, Xiangqi
    Sheng, Hansong
    Yin, Bo
    Zhang, Nu
    Lin, Jian
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [29] Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma
    Kim, Moonsik
    Yoo, Jihwan
    Chang, Jong Hee
    Kim, Se Hoon
    ANTICANCER RESEARCH, 2022, 42 (01) : 335 - 341
  • [30] Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas
    Qian, Zenghui
    Li, Yiming
    Fan, Xing
    Zhang, Chuanbao
    Wang, Yinyan
    Jiang, Tao
    Liu, Xing
    ONCOIMMUNOLOGY, 2018, 7 (06):
12345